Educational information, not medical advice — ask your doctor or midwife.
Track BPC-157 with reminders and record whether it helped, in the app.
BPC-157 is a 15-amino-acid synthetic peptide modeled after a sequence isolated from human gastric juice, where similar compounds are thought to play a protective role in the stomach lining. It has been studied extensively in preclinical research for its ability to speed up healing of tendons, muscles, ligaments, bones, and the gut lining. While large-scale human clinical trials are still limited, its track record in animal research is unusually consistent and robust, and its human gastric origin gives it a plausible biological rationale.
BPC-157 appears to work by promoting the growth of new blood vessels into damaged tissue (a process called angiogenesis), which restores blood flow and accelerates repair. It also supports the production of growth hormone receptors in healing tissue and helps regulate nitric oxide signaling, which reduces inflammation and supports vascular health. In the gut, it helps maintain and repair the mucosal lining, protecting against damage from injury, NSAIDs, and inflammatory conditions.
Injectable forms (subcutaneous or intramuscular) are most commonly used in research and by practitioners for musculoskeletal injuries. Oral capsules are increasingly popular for gut health applications. Nasal spray and topical preparations are emerging but have less research behind them. BPC-157 is not FDA-approved and is currently available primarily through compounding pharmacies or research chemical suppliers.
BPC-157 was first isolated and characterized by researchers at the University of Zagreb in the 1990s, led by Diogen Sikiric. The Zagreb team conducted a large body of preclinical research over the following decades, establishing its healing properties across multiple tissue types. It has not yet completed a Phase III human clinical trial but remains one of the most researched peptides in the preclinical literature.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
The published evidence for BPC-157 is weak or absent. That usually means no controlled trial has tested it, not that a trial found it ineffective — the two are different, and we grade only what has been published.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.